Chemotherapy-Induced Nausea and Vomiting—Pediatric

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and severe side effects of cancer treatment. CINV generally is classified as anticipatory, acute, delayed, breakthrough, and refractory. Chemotherapeutic regimens can be classified as having high, moderate, low, or minimal risk of emetogenicity. Incidence and timing of CINV vary according to patient factors and chemotherapeutic agents. Incidence has been reported in as high as 70%–80% of patients. Incidence of nausea tends to be higher than that of actual vomiting, and antiemetic medications tend to be less effective in controlling nausea.
Intervention research regarding chemotherapy-induced nausea and vomiting (CINV) in pediatric patients consist of studies with subjects who are younger than 18 years old.
ONS staff researchers and clinical specialists have exhaustively assessed evidenced-based research from comprehensive sources to provide you our best recommendations on Symptom Interventions for your patients.